Neuroprotective effect of estradiol and phytoestrogens on MPP+‐induced cytotoxicity in neuronal PC12 cells

A large body of experimental evidence supports a role for oxidative stress as a mediator of nerve cell death in Parkinson's disease. To better understand the cellular insult of oxidative stress on dopaminergic neurons, we studied the cytotoxic effect of the 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) metabolite, 1‐methyl‐4‐phenyl pyridium (MPP+), on several parameters of cell distress using neuronal PC12 cells. We also measured the level of protein expression for the dopamine transporter and the estrogen receptors α and β. Since estrogens have been reported to prevent neuronal degeneration caused by increased oxidative burden, we investigated the ability of 17β‐estradiol, the stereoisomer 17α‐estradiol, and several phytoestrogens to rescue neuronal PC12 cells submitted to MPP+‐induced cytotoxicity. Our results consistently show a protective effect of 17α‐estradiol, 17β‐estradiol and certain phytoestrogens such as quercetin and resveratrol, in neuronal PC12 cells treated with MPP+. In our cellular paradigm, phytoestrogens coumestrol, genistein, and kaempferol did not revert MPP+‐induced cellular death. By Western blot, we demonstrated that administration of MPP+ alone decrease dopamine transporter expression, while treatments with MPP+ together with 17α‐estradiol, 17β‐estradiol, quercetin, or resveratrol could restore dopamine transporter protein expression to control levels. Moreover, the same treatments did not modulate α estrogen receptor or β estrogen receptor expression. By these studies, we aim to provide more evidence for the involvement of phytoestrogens in the process of neuroprotection and to test our hypothesis that some of these compounds may act as neuroprotective molecules and have a lesser hormonal effect than estrogens. © 2002 Wiley‐Liss, Inc.

[1]  D. Allan Butterfield,et al.  Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins , 2001, Mechanisms of Ageing and Development.

[2]  L. Gollapudi,et al.  Stable transfection of PC12 cells with estrogen receptor (ERα): Protective effects of estrogen on cell survival after serum deprivation , 1999, Journal of neuroscience research.

[3]  K. Korach,et al.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.

[4]  T. Di Paolo,et al.  Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice , 2001, Synapse.

[5]  A. Collins,et al.  Antioxidant efficacy of phytoestrogens in chemical and biological model systems. , 1998, Archives of biochemistry and biophysics.

[6]  J. Le Bail,et al.  Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. , 2000, Life sciences.

[7]  P. Riederer,et al.  Free radicals in Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[8]  L. Gollapudi,et al.  Estrogen and NGF synergistically protect terminally differentiated, ERα‐transfected PC12 cells from apoptosis , 1999, Journal of neuroscience research.

[9]  B. Sherwin Estrogen effects on cognition in menopausal women , 1997, Neurology.

[10]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[11]  Y. Saito,et al.  Expression of dopamine transporter at the tips of growing neurites of PC12 cells. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[13]  K. Jellinger Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.

[14]  E. Nestler,et al.  Dopamine-receptor stimulation: biobehavioral and biochemical consequences , 2000, Trends in Neurosciences.

[15]  A. Bilancio,et al.  Protein Tyrosine Phosphorylation and Estradiol Action a , 1996, Annals of the New York Academy of Sciences.

[16]  N. Weigel Steroid hormone receptors and their regulation by phosphorylation. , 1996, The Biochemical journal.

[17]  T. Dawson,et al.  Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease , 2000, Neurobiology of Disease.

[18]  T. Di Paolo,et al.  Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. , 2000, Current pharmaceutical design.

[19]  T. Di Paolo,et al.  Sex and estrous cycle variations of rat striatal dopamine uptake sites. , 1993, Neuroendocrinology.

[20]  B. Goldin,et al.  Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. , 1997, Biochemical and biophysical research communications.

[21]  M. Beauregard,et al.  Effect of oxidative stress on stability and structure of neurofilament proteins. , 2000, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  Prahlad T. Ram,et al.  Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors , 1998, Molecular and Cellular Endocrinology.

[23]  G. Mor,et al.  Raloxifene Induces Neurite Outgrowth in, Estrogen Receptor Positive PC 12 Cells , 1998, Menopause.

[24]  R. Roth,et al.  Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory , 2000, The Journal of Neuroscience.

[25]  P. Whitten,et al.  Regulation of estrogen receptor beta mRNA in the brain: opposite effects of 17beta-estradiol and the phytoestrogen, coumestrol. , 1999, Brain research. Molecular brain research.

[26]  C. Behl,et al.  Neuroprotective activities of estrogen: An update , 2000, Journal of neurocytology.

[27]  T. Chun,et al.  Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. , 1998, Toxicology and applied pharmacology.

[28]  F. Holsboer,et al.  Neuroprotection against oxidative stress by estrogens: structure-activity relationship. , 1997, Molecular pharmacology.

[29]  K. Beck,et al.  Estradiol Enhances Learning and Memory in a Spatial Memory Task and Effects Levels of Monoaminergic Neurotransmitters , 1998, Hormones and Behavior.

[30]  L. Doncarlos,et al.  Neuroprotection by estradiol , 2001, Progress in Neurobiology.

[31]  Y. Kitamura,et al.  1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: Inhibitory effects of several drugs , 1994, Neurochemistry International.

[32]  M. Wade,et al.  Interactions between endosulfan and dieldrin on estrogen-mediated processes in vitro and in vivo. , 1997, Reproductive toxicology.

[33]  M. Morissette,et al.  Effect of Chronic Estradiol and Progesterone Treatments of Ovariectomized Rats on Brain Dopamine Uptake Sites , 1993, Journal of neurochemistry.

[34]  K. Chiba,et al.  Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. , 1985, Biochemical and biophysical research communications.

[35]  C. Behl,et al.  Estrogen Hormones Reduce Lipid Peroxidation in Cells and Tissues of the Central Nervous System , 1999, Journal of neurochemistry.

[36]  P. Blanchet,et al.  Effect of MPTP‐induced denervation on basal ganglia GABAB receptors: Correlation with dopamine concentrations and dopamine transporter , 2001, Synapse.

[37]  D. Dluzen,et al.  Inhibition of striatal dopamine transporter activity by 17beta-estradiol. , 1998, European journal of pharmacology.

[38]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[39]  C. Klinge,et al.  Resveratrol Acts as a Mixed Agonist / Antagonist for Estrogen Receptors a and b * , 2000 .

[40]  C. Behl,et al.  The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Alois Jungbauer,et al.  Regulation of human estrogen receptor by phytoestrogens in yeast and human cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  J. Trojanowski,et al.  Induction of neurofilament triplet proteins in PC12 cells by nerve growth factor , 1982, Brain Research.

[43]  N. Roehm,et al.  An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. , 1991, Journal of immunological methods.

[44]  L. Barrier,et al.  Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors , 2001, Neuroscience Letters.

[45]  E. Giacobini Aging, Alzheimer’s disease, and estrogen therapy , 1998, Experimental Gerontology.

[46]  J. M. Fuentes,et al.  Mechanisms of MPP+ incorporation into cerebellar granule cells , 2001, Brain Research Bulletin.

[47]  C. Fall,et al.  Characterization and time course of MPP+‐induced apoptosis in human SH‐SY5Y neuroblastoma cells , 1999, Journal of neuroscience research.

[48]  D. Dluzen,et al.  Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system , 2000, Journal of neurocytology.

[49]  D. Mash,et al.  Immunochemical analysis of dopamine transporter protein in Parkinson's disease , 1997, Annals of neurology.

[50]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[51]  M. Miller,et al.  Theoretical basis for the benefit of postmenopausal estrogen substitution , 1999, Experimental Gerontology.

[52]  S. Fahn,et al.  The effect of estrogen replacement on early Parkinson’s disease , 1999, Neurology.

[53]  R J Miller,et al.  The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. , 2000, Molecular pharmacology.

[54]  S. Bingham,et al.  Phyto-oestrogens: where are we now? , 1998, British Journal of Nutrition.

[55]  M. Beal,et al.  Mitochondrial dysfunction in neurodegenerative diseases. , 1998, Biochimica et biophysica acta.

[56]  P. Lin,et al.  The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. , 1998, Environmental health perspectives.

[57]  D. Dluzen,et al.  Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release , 1997, Brain Research.

[58]  A. Schapira,et al.  Mitochondrial dysfunction in neurodegenerative disorders. , 1998, Biochimica et biophysica acta.

[59]  M. Uhr,et al.  Neuroprotective potential of aromatic alcohols against oxidative cell death , 1997, FEBS letters.

[60]  Meharvan Singh,et al.  Novel Mechanisms of Estrogen Action in the Brain: New Players in an Old Story , 1999, Frontiers in Neuroendocrinology.

[61]  L. Frémont Biological effects of resveratrol. , 2000, Life sciences.